Skip to main content

Table 3 The blood purifications needed acute kidney injury cases in hematological malignancies

From: Methotrexate-induced acute kidney injury in patients with hematological malignancies: three case reports with literature review

Ref Underlying disease Listed risk factors Age y.o Sex Baseline sCr mg/dL Max. sCr mg/dL Abrupt sCr increase MTX dose g/m2 Max. MTX nmol/mL Blood purification modalities No. of times HD
QB
HD
QD
HD
h
DESA
m2
CPDG2 use
6 ALL NA 44 F NA NA UK 1.0 62 HD 1 400 500 4 1.8 No
6 CLL NA 72 M NA NA UK 1.0 1.5 HD 1 300 500 4 1.8 No
10 DLBCL NA 36 M 0.8 3.2 Yes 3.5 31 HD or HDF 8 150 NA 4 1.5 No
10 ALL NA 45 M 0.7 1.8 Yes 3.0 23 ChH 9 No
10 ALL NA 16 M 0.5 3.8 Yes 5.0 134 HD and ChH 3 180 NA 4 1.3 No
11 Histiocytoma NA 39 NA NA 2.6 UK 12 688 HD or HF 3 NA NA NA NA Yes
11 NHL NA 10 NA NA 4.7 UK 5.0 9.2 HD or HF 8 NA NA NA NA Yes
12 PCNSL TAZ/PIPC 58 M 0.7 3.1 Yes 2.5 93 ChH 4 Yes
12 ALbL Gemfibrozil 39 M 0.7 6.0 Yes 3.0 41 ChH 4 Yes
13 NHL NA 35 M 1.0 3.0 Yes 6.01 37 PE or CHDF 11 No
14 PCNSL NA 68 F 0.8 5.2 Yes 3.0 22 HD 2 NA NA NA NA Yes
* ALbL Lansoprazole cefepime 48 M 0.7 7.6 Yes 3.0 33 PE and/or HD 8 150 500 3 1.3 No
* MPAL Cefepime doripenem 19 M 0.6 6.9 Yes 3.0 9.5 PE or HD or ChH 5 150 500 3 1.3 No
* PCNSL UTI 72 F 0.5 2.0 Yes 2.0 7.7 PE and/or HD 7 150 500 3 1.1 No
  1. Risk factors are known to affect MTX clearance besides pre-performed chemotherapy
  2. *Reported in this paper; 1 per whole body
  3. y.o years old, Max. maximum, MTX methotrexate, No. number, HD hemodialysis, QB blood flow (mL/min), QD dialysate flow (mL/min), DESA dialyzer effective surface area (m2), CPDG2 carboxypetidase-G2, NA not available, UK unknown, CLL chronic lymphocytic leukemia, DLBCL diffuse large B cell lymphoma, ALL acute lymphocytic leukemia, NHL non-Hodgkin lymphoma, PCNSL primary central nervous system lymphoma, ALbL acute lymphoblastic leukemia, MPAL mixed-phenotype acute leukemia, TAZ/PIPC tazobactam/ piperacillin, UTI urinary tract infection, ChH charcoal hemoperfusion, HDF hemodiafiltration, HF hemofiltration, PE plasma exchange, CHDF continuous hemodiafiltration